A Study of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors
A Phase I/II, First-in-Human (FIH), Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors
For Phase I, to assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-364 as a single agent or in combination with tislelizumab in participants with advanced solid tumors.
For Phase II, to assess the preliminary anti-tumor activity of IMP in participants with advanced solid tumors.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Alex Yuan
- Phone Number: +8615901815211
- Email: alexyuan@lanovamed.com
Study Locations
-
-
New South Wales
-
North Ryde, New South Wales, Australia
- Macquarie University
-
Contact:
- Dhanusha Sabanathan
-
Wollongong, New South Wales, Australia
- Cancer Care Wollongong Hospital
-
Contact:
- Udit Nindra
-
-
Queensland
-
Brisbane, Queensland, Australia
- ICON Cancer Centre South Brisbane
-
Contact:
- Jermaine Coward
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants who are willing to participate in the study and sign the informed consent form (ICF) prior to any procedure.
- Participants must be ≥18 years or the legal age of consent at the time of signing the ICF.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Life expectancy ≥ 3 months.
- Adequate organ and bone marrow function as defined by protocol.
- Participants who are able to communicate well with investigators and understand and adhere to the requirements of this study.
Exclusion Criteria:
- Participant in any other clinical trial within 28 days prior to 1st dosing of LM-364.
- Any adverse event from prior anti-tumour therapy has not yet recovered to ≤ grade 1 of CTCAE v6.0.
- Participants with uncontrolled tumour-related pain.
- Use of any live attenuated vaccines within 28 days prior to 1st dosing of LM-364.
- Participants who received major surgery or interventional treatment within 28 days prior to 1st dosing of LM-364.
- Participants who have severe cardiovascular disease.
- Participants who have uncontrolled or severe illness.
- Participants who have a history of immunodeficiency disease.
- Participants with a known history of autoimmune disease.
- Participants who have other active malignancies which are likely to require the treatment.
- Child-bearing potential female who have positive results in pregnancy test or are lactating.
- Participants who have psychiatric illness or disorders that may preclude study compliance.
- Participants who is judged as not eligible to participate in this study by the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: LM-364 Monotherapy
|
Q3W, Intravenous Drip
|
|
Experimental: LM-364 Combination Therapy
|
Q3W, Intravenous Drip
Q3W, Intravenous Drip
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Temperature (Celsius)
Time Frame: 78 weeks
|
Phase I
|
78 weeks
|
|
Pulse in BPM(Beat per Minute)
Time Frame: 78 weeks
|
Phase I
|
78 weeks
|
|
Blood Pressure in mmHg
Time Frame: 78 weeks
|
Phase I
|
78 weeks
|
|
Weight in Kg
Time Frame: 78 weeks
|
Phase I
|
78 weeks
|
|
12-lead electrocardiogram (ECG) in HR
Time Frame: 78 weeks
|
Phase I
|
78 weeks
|
|
12-lead electrocardiogram (ECG) in RR
Time Frame: 78 weeks
|
Phase I
|
78 weeks
|
|
12-lead electrocardiogram (ECG) in QRS
Time Frame: 78 weeks
|
Phase I
|
78 weeks
|
|
12-lead electrocardiogram (ECG) in QT
Time Frame: 78 weeks
|
Phase I
|
78 weeks
|
|
12-lead electrocardiogram (ECG) in QTcF
Time Frame: 78 weeks
|
Phase I
|
78 weeks
|
|
ECOG(Eastern Cooperative Oncology Group) score
Time Frame: 78 weeks
|
Phase I
|
78 weeks
|
|
Incidence of Treatment-Emergent Adverse Events (AEs)
Time Frame: 78 weeks
|
Phase I
|
78 weeks
|
|
Incidence of serious adverse events (SAEs)
Time Frame: 78 weeks
|
Phase I
|
78 weeks
|
|
Blood Routine examination -> Complete Blood Count
Time Frame: 78 weeks
|
Phase I
|
78 weeks
|
|
Urine Routine examination ->Urinalysis
Time Frame: 78 weeks
|
Phase I
|
78 weeks
|
|
Blood Biochemistry test -> Electrolytes and Metabolic Parameters
Time Frame: 78 weeks
|
Phase I
|
78 weeks
|
|
Pregnancy test
Time Frame: 78 weeks
|
Phase I
|
78 weeks
|
|
Objective Response Rate (ORR)
Time Frame: 130 weeks
|
Phase II
|
130 weeks
|
|
Incidence of dose-limiting toxicity (DLT)
Time Frame: 78 weeks
|
Phase I
|
78 weeks
|
|
Height in centimeters
Time Frame: 78 weeks
|
Phase I
|
78 weeks
|
|
Coagulation function test-For the detection of Prothrombin time (PT), Activated partial thromboplastin time (APTT),
Time Frame: 78 weeks
|
Phase I
|
78 weeks
|
|
Thyroid Function Test-For the detection of thyroid-stimulating hormone (TSH), free triiodothyronine (FT3) and free thyroxine (FT4)
Time Frame: 78 weeks
|
Phase I
|
78 weeks
|
|
Echocardiography- LVEF (Left Ventricular Ejection Fraction) in percentage
Time Frame: 78 weeks
|
Phase I
|
78 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pharmacokinetic (PK) Parameter: Maximum Observed Concentration (Cmax)
Time Frame: 130 weeks
|
Phase I/II
|
130 weeks
|
|
PK Parameter:Time of Maximum Observed Concentration (Tmax)
Time Frame: 130 weeks
|
Phase I/II
|
130 weeks
|
|
PK Parameter: Systemic Clearance at Steady State (CLss)
Time Frame: 130 weeks
|
Phase I/II
|
130 weeks
|
|
PK Parameter: Accumulation Ratio (Rac)
Time Frame: 130 weeks
|
Phase I/II
|
130 weeks
|
|
PK Parameter: Elimination Half-life (t1/2)
Time Frame: 130 weeks
|
Phase I/II
|
130 weeks
|
|
PK Parameter: Volume of Distribution at Steady-State (Vss)
Time Frame: 130 weeks
|
Phase I/II
|
130 weeks
|
|
PK Parameter: Degree of Fluctuation (DF)
Time Frame: 130 weeks
|
Phase I/II
|
130 weeks
|
|
Duration of Response (DOR) in Month
Time Frame: 130 weeks
|
Phase I/II
|
130 weeks
|
|
Disease control rate (DCR) in percentage
Time Frame: 130 weeks
|
Phase I/II
|
130 weeks
|
|
Changes of target lesions from baseline in Millimeter
Time Frame: 130 weeks
|
Phase I/II
|
130 weeks
|
|
Immunogenicity testing->Anti-Drug Antibody test
Time Frame: 130 weeks
|
Phase I/II
|
130 weeks
|
|
Progression-free survival (PFS) in Month
Time Frame: 130 weeks
|
Phase I/II
|
130 weeks
|
|
Incidence of adverse events (AEs)
Time Frame: 130 weeks
|
Phase II
|
130 weeks
|
|
Incidence of serious adverse events (SAEs)
Time Frame: 130 weeks
|
Phase II
|
130 weeks
|
|
Temperature (Celsius)
Time Frame: 130 weeks
|
Phase II
|
130 weeks
|
|
Pulse in BPM(Beat per Minute)
Time Frame: 130 weeks
|
Phase II
|
130 weeks
|
|
Blood Pressure in mmHg
Time Frame: 130 weeks
|
Phase II
|
130 weeks
|
|
Weight in Kg
Time Frame: 130 weeks
|
Phase II
|
130 weeks
|
|
Blood Routine examination -> Complete Blood Count
Time Frame: 130 weeks
|
Phase II
|
130 weeks
|
|
Urine Routine examination ->Urinalysis
Time Frame: 130 weeks
|
Phase II
|
130 weeks
|
|
Blood Biochemistry test -> Electrolytes and Metabolic Parameters
Time Frame: 130 weeks
|
Phase II
|
130 weeks
|
|
Coagulation function test-For the detection of Prothrombin time (PT), Activated partial thromboplastin time (APTT), International normalized ratio (INR)
Time Frame: 130 weeks
|
Phase II
|
130 weeks
|
|
Pregnancy test
Time Frame: 130 weeks
|
Phase II
|
130 weeks
|
|
ECOG(Eastern Cooperative Oncology Group) score
Time Frame: 130 weeks
|
Phase II
|
130 weeks
|
|
12-lead electrocardiogram (ECG) in HR
Time Frame: 130 weeks
|
Phase II
|
130 weeks
|
|
12-lead electrocardiogram (ECG) in RR
Time Frame: 130 weeks
|
Phase II
|
130 weeks
|
|
12-lead electrocardiogram (ECG) in PR
Time Frame: 130 weeks
|
Phase II
|
130 weeks
|
|
12-lead electrocardiogram (ECG) in QRS
Time Frame: 130 weeks
|
Phase II
|
130 weeks
|
|
12-lead electrocardiogram (ECG) in QT
Time Frame: 130 weeks
|
Phase II
|
130 weeks
|
|
12-lead electrocardiogram (ECG) in QTcF
Time Frame: 130 weeks
|
Phase II
|
130 weeks
|
|
Biomarker test -> Tumor tissue biomarker test
Time Frame: 130 weeks
|
Phase I/II
|
130 weeks
|
|
Overall survival (OS) in Month
Time Frame: 130 weeks
|
Phase I/II
|
130 weeks
|
|
PK Parameter: Area Under the Concentration-time Curve (AUC)
Time Frame: 130 weeks
|
Phase I/II
|
130 weeks
|
|
PK Parameter: Steady State Maximum Concentration (Cmax,ss) PK Parameter: Steady State Maximum Concentration(Cmax,ss)
Time Frame: 130 weeks
|
Phase I/II
|
130 weeks
|
|
PK Parameter: Steady State Minimum Concentration (Cmin,ss)
Time Frame: 130 weeks
|
Phase I/II
|
130 weeks
|
|
Objective Response Rate (ORR)
Time Frame: 130 weeks
|
Phase I/II
|
130 weeks
|
|
Height in centimeters
Time Frame: 130 weeks
|
Phase II
|
130 weeks
|
|
Thyroid Function Test-For the detection of thyroid-stimulating hormone (TSH), free
Time Frame: 130 weeks
|
Phase II
|
130 weeks
|
|
Echocardiography- LVEF (Left Ventricular Ejection Fraction) in percentage
Time Frame: 130 weeks
|
Phase II
|
130 weeks
|
|
QTc-PK relationship -> Correlation concentrations (total antibody, free DXd) vs ΔQTcF (Fridericia's correction)
Time Frame: 12 weeks
|
Phase I
|
12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- LM364-01-101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.